158 related articles for article (PubMed ID: 37690180)
41. Radiation and immunotherapy combinations in non-small cell lung cancer.
Azghadi S; Daly ME
Cancer Treat Res Commun; 2021; 26():100298. PubMed ID: 33387868
[TBL] [Abstract][Full Text] [Related]
42. Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
Iyengar P; Wardak Z; Gerber DE; Tumati V; Ahn C; Hughes RS; Dowell JE; Cheedella N; Nedzi L; Westover KD; Pulipparacharuvil S; Choy H; Timmerman RD
JAMA Oncol; 2018 Jan; 4(1):e173501. PubMed ID: 28973074
[TBL] [Abstract][Full Text] [Related]
43. Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR).
Alomran R; White M; Bruce M; Bressel M; Roache S; Karroum L; Hanna GG; Siva S; Goel S; David S
BMC Cancer; 2021 Mar; 21(1):303. PubMed ID: 33757458
[TBL] [Abstract][Full Text] [Related]
44. Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer.
Kagawa Y; Furuta H; Uemura T; Watanabe N; Shimizu J; Horio Y; Kuroda H; Inaba Y; Kodaira T; Masago K; Fujita S; Niimi A; Hida T
Cancer Sci; 2020 Dec; 111(12):4442-4452. PubMed ID: 32770608
[TBL] [Abstract][Full Text] [Related]
45. EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases.
Jiang T; Chu Q; Wang H; Zhou F; Gao G; Chen X; Li X; Zhao C; Xu Q; Li W; Wu F; Xiong A; Zhao J; Xu Y; Su C; Ren S; Zhou C; Hirsch FR
Int J Cancer; 2019 May; 144(10):2605-2612. PubMed ID: 30387880
[TBL] [Abstract][Full Text] [Related]
46. The Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively?
Patel PH; Palma D; McDonald F; Tree AC
Clin Oncol (R Coll Radiol); 2019 Dec; 31(12):824-833. PubMed ID: 31182289
[TBL] [Abstract][Full Text] [Related]
47. Long-term Local Control and Overall Survival After Radiotherapy in Oligoprogressive Patients During Treatment With Checkpoint Inhibitors.
Damen PJJ; Suijkerbuijk KPM; VAN Lindert ASR; Eppinga WSC; El Sharouni SY; Verhoeff JJC
Anticancer Res; 2022 Oct; 42(10):4795-4804. PubMed ID: 36191990
[TBL] [Abstract][Full Text] [Related]
48. Endoscopic nodal staging in oligometastatic non-small cell lung cancer (NSCLC) being treated with stereotactic ablative radiotherapy (ENDO-SABR).
Dhaliwal I; Kassirian S; Mitchell MA; Qiabi M; Warner A; Louie AV; Wong HH; McDonald CM; Rajchgot J; Palma DA
BMC Cancer; 2022 Apr; 22(1):468. PubMed ID: 35484614
[TBL] [Abstract][Full Text] [Related]
49. Current and future research efforts in oligometastatic non-small cell lung cancer-a systematic review.
Brandão M; Durieux V; Berghmans T
Transl Lung Cancer Res; 2021 Jul; 10(7):3473-3485. PubMed ID: 34430381
[TBL] [Abstract][Full Text] [Related]
50. The Management of Oligometastases in Non-small Cell Lung Cancer - is Stereotactic Ablative Radiotherapy now Standard of Care?
Ratnakumaran R; McDonald F
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):753-760. PubMed ID: 36117126
[TBL] [Abstract][Full Text] [Related]
51. Radical treatment of oligometastatic non-small cell lung cancer: Ready for prime time?
Brighenti M; Petrelli F; Barni S; Conti B; Sarti E; Ratti M; Panni S; Passalacqua R; Bersanelli M
Eur J Cancer; 2017 Jul; 79():149-151. PubMed ID: 28494405
[TBL] [Abstract][Full Text] [Related]
52. Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L).
Miyawaki T; Kenmotsu H; Harada H; Ohde Y; Chiba Y; Haratani K; Okimoto T; Sakamoto T; Wakuda K; Ito K; Uemura T; Sakata S; Kogure Y; Nishimura Y; Nakagawa K; Yamamoto N
BMC Cancer; 2021 Oct; 21(1):1121. PubMed ID: 34663250
[TBL] [Abstract][Full Text] [Related]
53. Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions.
Donini M; Buti S; Massari F; Mollica V; Rizzo A; Montironi R; Bersanelli M; Santoni M
Expert Rev Anticancer Ther; 2020 Jun; 20(6):491-501. PubMed ID: 32479120
[TBL] [Abstract][Full Text] [Related]
54. Characterization of Metastatic Non-Small Cell Lung Cancer and Oligometastatic Incidence in an Era of Changing Treatment Paradigms.
No HJ; Raja N; Von Eyben R; Das M; Roy M; Myall N; Neal J; Wakelee H; Chin A; Diehn M; Loo BW; Chang DT; Pollom EL; Vitzthum LK
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):603-610. PubMed ID: 35654305
[TBL] [Abstract][Full Text] [Related]
55. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.
Blake-Cerda M; Lozano-Ruíz F; Maldonado-Magos F; de la Mata-Moya D; Díaz-García D; Lara-Mejía L; Zatarain-Barrón ZL; Cuevas-Góngora MF; Barron-Barron F; Corona-Cruz JF; Cabrera-Miranda L; Arroyo-Hernández M; Gerson R; Arrieta O
Lung Cancer; 2021 Feb; 152():119-126. PubMed ID: 33385737
[TBL] [Abstract][Full Text] [Related]
56. Advances and Challenges in Trials of Local Therapy for Patients With Oligometastatic or Oligoprogressive Disease.
Yan M; Abdel-Rahman F; Dawson L; Wong P; Wong RKS; Tsai CJ
Semin Radiat Oncol; 2023 Oct; 33(4):416-428. PubMed ID: 37684071
[TBL] [Abstract][Full Text] [Related]
57. Effect of Stereotactic Body Radiation Therapy on Diverse Organ Lesions in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
Zhu KK; Wei JL; Xu YH; Li J; Rao XR; Xu YZ; Xing BY; Zhang SJ; Chen LC; Dong XR; Zhang S; Li ZY; Liu CW; Meng R; Wu G
Curr Med Sci; 2023 Apr; 43(2):344-359. PubMed ID: 37002471
[TBL] [Abstract][Full Text] [Related]
58. Stereotactic radiotherapy in oligoprogressive and oligorecurrent urothelial cancer patients: A retrospective experience.
Francolini G; Desideri I; Detti B; Di Cataldo V; Masi L; Caramia G; Visani L; Terziani F; Muntoni C; Lo Russo M; Loi M; Livi L
Cancer Treat Res Commun; 2019; 19():100124. PubMed ID: 30851645
[TBL] [Abstract][Full Text] [Related]
59. The use of radiation therapy for oligoprogressive/oligopersistent oncogene-driven non small cell lung cancer: State of the art.
Franceschini D; De Rose F; Cozzi S; Franzese C; Rossi S; Finocchiaro G; Toschi L; Santoro A; Scorsetti M
Crit Rev Oncol Hematol; 2020 Apr; 148():102894. PubMed ID: 32062314
[TBL] [Abstract][Full Text] [Related]
60. The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review.
Le Guevelou J; Sargos P; Siva S; Ploussard G; Ost P; Gillessen S; Zilli T
Eur Urol Focus; 2023 Jan; 9(1):114-124. PubMed ID: 36151031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
